Pediatric Liver Tumors and Treatment Outcomes

Pediatric liver tumours are rare but represent a significant cause of childhood cancer mortality, with hepatoblastoma accounting for the majority of cases and hepatocellular carcinoma constituting a smaller proportion. Advances in imaging, surgical techniques and risk-adapted chemotherapy have raised five-year survival rates above 80% in developed countries, yet outcomes remain poor for patients with high-risk disease, metastatic spread or chemoresistant tumours. Standard treatment comprises platinum-based regimens often combined with doxorubicin, followed by complete surgical resection or orthotopic liver transplantation when feasible. Molecular profiling has revealed distinct subtypes of hepatoblastoma characterised by Wnt/β-catenin pathway activation, variable telomerase reverse transcriptase promoter mutations and epigenetic dysregulation. These insights are driving the development of targeted approaches, including inhibitors of histone methyltransferases and agents that exploit metabolic vulnerabilities. Emerging strategies integrate genomic risk stratification with tailored combinations of chemotherapy, targeted therapy and immunomodulatory drugs, aiming to maximise cure rates while reducing long-term toxicity.

Research from Nature Portfolio

Recent studies have mapped genetic dependencies in high-risk hepatoblastoma using CRISPR–Cas9 screening in an improved MYC-driven murine model. This approach identified druggable targets such as CDK7, PRMT5 and PRKDC, and demonstrated synergistic enhancement of doxorubicin efficacy through PRKDC inhibition. Single-cell transcriptomics in the same model uncovered cellular subpopulations with distinct gene-expression programmes, informing potential combination therapies. In parallel, integrative genomic and epigenomic profiling of over 150 paediatric liver tumours delineated molecular subgroups with varied prognoses. Classical hepatoblastomas exhibited hypomethylated enhancers enriched for ASCL2 binding, whereas aggressive subtypes showed fetal-liver-like methylation at IGF2 promoters. These findings underpin novel risk stratification schemes and highlight epigenetic drivers as therapeutic entry points.

Pediatric Liver Tumors and Treatment Outcomes publication trend

The graph below shows the total number of articles in pediatric liver tumors and treatment outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatoblastoma: The most common primary malignant liver tumour in children, arising from embryonic liver precursor cells.

Histone methyltransferase G9a: An enzyme that catalyses methylation of histone H3 lysine 9, affecting chromatin structure and gene expression.

CRISPR–Cas9 screening: A genome-wide functional assay using CRISPR–Cas9 to identify gene dependencies and modifiers of drug response.

Patient-derived xenograft (PDX): A model in which human tumour tissue is implanted into immunodeficient mice to study cancer biology and treatment efficacy.

DNA methylation: An epigenetic modification involving the addition of methyl groups to cytosine residues, influencing gene regulation and tumour behaviour.

References

1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. Journal of Hepatology (2023).
2. Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma. Journal of Experimental & Clinical Cancer Research (2024).
3. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma. Nature Communications (2023).
4. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. npj Precision Oncology (2020).
5. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology (2016).
6. Hepatoblastoma—The Evolution of Biology, Surgery, and Transplantation. Children (2018).
7. Incidence trends and survival prediction of hepatoblastoma in children: a population‐based study. Cancer Communications (2019).